RT Journal Article
T1 Medium-term clinical outcomes following Xen45 device implantation
A1 Fernández García, Aitor
A1 Zhou, Ying
A1 García Alonso, Mercedes
A1 Andrango, Henry D.
A1 Poyales Galán, Francisco
A1 Garzón Jiménez, Nuria
AB Purpose: To evaluate medium-term clinical outcomes with microstent XEN® 45 Gel Stent (Allergan Dublin, Ireland) for treatment of primary open-angle glaucoma (POAG).Material and methods: This is a retrospective, descriptive and observational study involving 93 eyes from 63 patients who had undergone POAG surgery with a XEN® 45 Gel Stent implantation and had been followed up and controlled between 12 and 36 months.Results: IOP dropped from 18.23 ± 5.00 mmHg pre-op to 14.16 ± 2.14, 14.47 ± 2.16 and 14.63 ± 1.91 at 1, 2 and 3 years after surgery (p = 0.000, 0.000 and 0.001) consecutively. Mean number of medications dropped from 1.87 ± 0.94 preoperatively to 0.31 ± 0.69, 0.34 ± 0.63 and 1.00 ± 0.88 (p = 0.000, 0.000 and 0.017) at 12, 24 and 36 months. Mean visual field deviation values never turned out to be significant for any of the follow-up visit data. A total of 94.6% of the surgical procedures turned out to be complication-free. In one surgery, the procedure failed and 18 months later other device was implanted.Conclusion: POAG surgical procedures with XEN® 45 Gel Stent implants are a safe and effective treatment approach.
PB Springer Verlag
SN 0165-5701
YR 2019
FD 2019-11
LK https://hdl.handle.net/20.500.14352/5978
UL https://hdl.handle.net/20.500.14352/5978
LA eng
NO Received: 7 august 2019; Accepted: 16 november 2019
DS Docta Complutense
RD 27 dic 2025